Boston Life Sciences Strengthens Board of Directors and Management Team; Professor Robert Langer Joins Board of Directors.

Business/Technology Editors & Health/Medical Writers

BIOWIRE2K

BOSTON--(BW HealthWire)--Feb. 23, 2000

Boston Life Sciences, Inc. (NASDAQ: BLSI) announced that Professor Robert Langer has joined its Board of Directors. Professor Langer is the Kenneth J. Germeshausen Professor of Chemical and Biomedical Engineering at MIT. He received a Bachelor's Degree from Cornell University in 1970 and a Sc.D. from MIT in 1974, both in chemical engineering. He is the only engineer to receive the Gairdner Foundation International Award (52 recipients of this award have subsequently received a Nobel Prize), and he received the Lemelson-MIT Prize, the world's largest prize for invention. In 1989, Dr. Langer was elected to the Institute of Medicine and the National Academy of Sciences, and in 1992 he was elected to both the National Academy of Engineering and to the National Academy of Sciences. "We are delighted to expand the tremendous benefit that BLSI has derived from its longstanding relationship with Dr. Langer. We are honored to obtain even more of his guidance and expertise," commented David Hillson, President and Chief Executive Officer of BLSI.

Brian L. Hamilton, M.D., Ph.D., has joined BLSI as Director of Medical and Regulatory Affairs. He has held positions as Director of Clinical Research at Alkermes, Inc., and Associate Director of Clinical Research at Astra Pharmaceuticals prior to joining Boston Life Sciences. Earlier in his academic career, Dr. Hamilton's appointments included Assistant Professor at the University of Washington School of Medicine, and Associate Professorship at the University of Miami School of Medicine and the University of California San Francisco School of Medicine. Dr. Hamilton is boarded in Pediatrics and Allergy/Immunology.

Anthony Helstosky has joined Boston Life Sciences as Associate Director of Regulatory Affairs. Mr. Helstosky has more than 20 years of industry experience in biotechnology and pharmaceutical research and development. Most recently he was Senior Director of Clinical Operations at Genzyme Corporation. He previously held a variety of clinical, regulatory and project management positions at Astra Pharmaceuticals and Sterling-Winthrop.

Samuel Martin, CPA has joined the Company as Corporate Controller. Most recently, he was an Audit Manager in the Entrepreneurial Services Group for Ernst & Young in Boston.

"We expect to achieve a number of important clinical milestones in 2000, and have significantly strengthened our Board and management team to help us achieve their timely and efficient execution," stated David Hillson, President and CEO of BLSI. The Company's clinical objectives for 2000 include:

--Completion of the ongoing Phase III clinical trial for Altropane(TM) as a diagnostic for Parkinson's Disease, and the submission of an NDA

--Completion of 2 Phase II trials for Altropane as a diagnostic for Attention Deficit Hyperactivity Disorder ("ADHD")

--Initiation of a Phase I clinical trial for Troponin, BLSI's naturally occurring anti-angiogenic factor for the treatment of cancer

--Submission of an IND for AF-1 and Inosine, the Company's nerve growth factors for the treatment of glaucoma and spinal cord injury 

BLSI is developing novel diagnostics and therapeutics for Parkinson's Disease and Attention Deficit Hyperactivity Disorder (ADHD) as well as treatments for cancer, autoimmune diseases, and central nervous system disorders. BLSI's products in development include: Altropane, a radioimaging agent for the diagnosis of Parkinson's Disease and ADHD; Troponin I, a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine, nerve growth factors for the treatment of acute and chronic CNS disorders; fusion toxins for the treatment of cancer and multiple sclerosis; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies.

Statements made in this press release other than statements of historical fact represent forward-looking statements. Such statements include, without limitation, statements regarding expectations or beliefs as to future results or events, such as the expected timing and results of clinical trials, discussions with regulatory agencies, schedules of IND, NDA and all other regulatory submissions, the timing of product introductions, the possible approval of products, and the market size and possible advantages of the Company's products. All such forward-looking statements involve substantial risks and uncertainties and actual results may vary materially from these statements. Factors that may affect future results include: the availability and adequacy of financial resources, the ability to obtain intellectual property protection, delays in the regulatory or development processes, results of scientific data from clinical trials, regulatory decisions, the outcome of discussions with potential partners, market acceptance of the Company's products and other possible risks and uncertainties that have been noted in reports filed by the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K/A.